Polyketide compounds having anti-inflammatory activity and methods for producing and using same

Isolation and purification of polyketide compounds from Penicillium sp. HJT-A-10 through fermentation and chromatography yield novel anti-inflammatory agents, effectively inhibiting nitric oxide release, addressing the need for new anti-inflammatory compounds.

JP2024542325AActive Publication Date: 2024-11-14DALIAN UNIV

Patent Information

Application Number
JP2024533328
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-13
Filing Date
2022-06-28
Publication Date
2024-11-14
Estimated Expiration
2042-06-28

AI Technical Summary

Technical Problem

There is a need for new anti-inflammatory compounds derived from plant endophytic bacterial resources to address inflammatory conditions effectively.

Method used

Isolation and purification of polyketide compounds from Penicillium sp. HJT-A-10, deposited as CGMCC No. 40167, through solid-state fermentation and chromatographic methods, yielding four novel compounds with anti-inflammatory activity.

Benefits of technology

The isolated polyketide compounds demonstrate significant anti-inflammatory activity, with compound 3 showing superior inhibitory effects on nitric oxide release at 10 μM concentration, providing a new approach for developing anti-inflammatory drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542325000001_ABST
    Figure 2024542325000001_ABST
Patent Text Reader

Abstract

The present invention discloses a polyketide compound with anti-inflammatory activity and its preparation and use, which belongs to the field of pharmaceutical technology. The present invention isolates Penicillium sp. HJT-A-10 from the root of Rhodiola tibetica, and the obtained Penicillium sp. HJT-A-10 is subjected to solid fermentation, and separated by a series of separation and purification methods to obtain four novel active compounds, all of which have good anti-inflammatory activity, providing a new approach for the development of anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of pharmaceutical technology, specifically to polyketide compounds having anti-inflammatory activity and their preparation and use. [Background technology]

[0002] Medicinal plant endophytic fungi are diverse, and each endophytic fungus has a wealth of secondary metabolites, and currently, a large number of biologically active substances such as alkaloids, polypeptides, polyketides, and terpenoids have been discovered from the secondary metabolites of endophytic fungi, and these secondary metabolites not only have the same or similar biological activities as those of the host plant, such as antibacterial, anti-inflammatory, antitumor, antihyperglycemic, and antiparasitic, but also have many new biological activities. Therefore, the secondary metabolites of medicinal plant endophytic fungi are a huge potential medicinal substance resource storehouse, with good prospects for development. Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention has been made in view of the above, and aims to provide a polyketide compound with anti-inflammatory activity, and its preparation and use. The present invention is to study plant endophytic fungi in order to fully utilize plant endophytic fungal resources, and isolate Penicillium sp. HJT-A-10 from the root part of Rhodiola tibetica, which was deposited in the General Microorganism Center of the China Committee for the Preservation and Management of Microorganisms on May 6, 2022, with the deposit number CGMCC No. 40167, and the depository address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing. The obtained Penicillium sp. HJT-A-10 is subjected to solid fermentation, and is separated using a series of separation and purification methods to obtain four new active compounds, providing new lead compounds for the development of drugs. [Means for solving the problem]

[0004] The object of the present invention can be achieved by the following technical means.

[0005] According to one aspect of the present invention, there is provided a polyketide compound having the structure shown in the formula below, or a pharma- ceutically acceptable salt thereof. [ka]

[0006] According to another aspect of the present invention, there is provided an endophytic fungus of the genus Penicillium (Penicillium sp.) HJT-A-10, which was deposited at the Center of Ordinary Microorganisms of the China Commission for the Preservation and Management of Microbial Species on May 6, 2022, with the deposit number CGMCC No. 40167, and the address of the depository institution is No. 3, Hall No. 1, Beichen West Road, Chaoyang District, Beijing.

[0007] According to another aspect of the present invention, there is further provided a method for producing the polyketide compound, which mainly comprises the following steps (1) and (2): Step (1): The above-mentioned Penicillium sp. HJT-A-10 is inoculated into a rice solid medium and cultivated to obtain a solid fermentation product. Step (2): The extract of the solid fermentation product obtained in step (1) is loaded onto a normal-phase silica gel column, and gradient elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 100:0 to 100:100. Fractions 1 to 5 are obtained in sequence according to the TLC results. Then, fraction 5 is loaded onto a normal-phase silica gel column, and gradient elution is performed using a mobile phase of petroleum ether / ethyl acetate with a volume ratio of 15:1 to 2:1. Fractions 5-1 to 5-7 are obtained in sequence according to the TLC results. Fraction 5-3 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 1:1. Fraction 5-3-2 is obtained according to the TLC results. Fraction 5-3-2 is loaded onto an Agilent C18 high-performance liquid chromatography column, and elution is performed using a mobile phase of 35% aqueous methanol to obtain compound 1. Fraction 5-7 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a mobile phase of 35% aqueous methanol to obtain compound 2. Loaded on a LH-20 gel column, eluted with a 1:1 volumetric ratio of dichloromethane / methanol mixture as the mobile phase, and obtained fraction 5-7-3 according to the TLC results. Loaded fraction 5-7-3 on an Agilent C18 high performance liquid chromatography column, eluted with a 25% aqueous acetonitrile solution as the mobile phase, and obtained compound 2 and compound 3. Loaded fraction 5-4 on a Sephadex LH-20 gel column, eluted with a 1:1 volumetric ratio of dichloromethane / methanol mixture as the mobile phase, and obtained fraction 5-4-2 according to the TLC results. Loaded fraction 5-4-2 on an Agilent C18 high performance liquid chromatography column, eluted with a 35% aqueous acetonitrile solution as the mobile phase, and obtained compound 4.

[0008] Furthermore, the solid rice medium in step (1) is obtained by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / mL.

[0009] Furthermore, during the loading process in step (2), 100-200 mesh silica gel is added to the extract of the solid fermentation product, stirred, the solvent is evaporated to dryness, and the mixture is packed into a column.

[0010] Furthermore, during the gradient elution in step (2), the volume ratio of dichloromethane to methanol is 100:0, 100:1, 100:2, 100:3, 100:4, 100:5, 100:7, 100:10, 100:20, 100:50, and 100:100.

[0011] Furthermore, during the above gradient elution in step (2), the volume ratios of petroleum ether to ethyl acetate are 15:1, 10:1, 8:1, 6:1, 4:1, and 2:1.

[0012] The present invention further provides a pharmaceutical composition comprising the above polyketide compound or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0013] The present invention further provides use of the above-mentioned polyketide compound, or a pharma- ceutically acceptable salt or pharmaceutical composition thereof for the manufacture of an anti-inflammatory drug. Effect of the Invention

[0014] Compared with the prior art, the present invention has the following advantages: 1. By studying plant endophytic fungi, the present invention utilizes plant endophytic fungal resources, and four novel active compounds are isolated, providing new lead compounds for drug development. 2. The four compounds isolated by the present invention inhibited NO release to different degrees depending on the concentration, and compound 3 showed better inhibitory activity than the positive control group at a concentration of 10 μM. This demonstrates that all four compounds of the present invention have good anti-inflammatory activity, providing a new approach for the development of anti-inflammatory drugs. [Brief description of the drawings]

[0015] In order to more clearly explain the embodiments of the present invention, the drawings relating to the embodiments will be briefly described below.

[0016] [Figure 1] FIG. 1 shows the anti-inflammatory effects of compounds 1 to 4 isolated in Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] The present invention will be described in detail below with reference to examples, but the embodiments of the present invention are not limited thereto. The examples described below are only a part of the examples of the present invention, and it is obvious that other similar examples obtained by those skilled in the art without creative labor are included in the scope of protection of the present invention. Unless otherwise stated, all experimental methods used in the present invention are conventional methods, and all experimental equipment, materials, reagents, etc. used are commercially available.

[0018] Example 1 The method for producing a polyketide compound mainly includes steps (1) and (2).

[0019] Step (1): Penicillium sp. HJT-A-10 is inoculated into a solid medium prepared by mixing rice and pure water in a mass / volume ratio of 80 g:100 ml, and cultured to obtain a solid fermentation product.

[0020] Step (2): The solid fermentation product obtained in step (1) is dissolved in methanol / dichloromethane with a volume ratio of 1:1, then 100-200 mesh silica gel is added and stirred, the solvent is evaporated to dryness, and the solid fermentation product is separated by a normal phase silica gel column, where the mobile phase is dichloromethane / methanol, and the volume ratio of dichloromethane to methanol is 100:0, 100:1, 100:2, 100:3, 100:4, 100:5, 100:7, 100:10, 100:20, 100:30, 100:40, 100:50, 100:60, 100:70, 100:80, 100:90, 100:100, 100:110, 100:120, 100:130, 100:140, 100:150, 100:160, 100:170, 100:180, 100:190, 100:200, 100:210, 100:220, 100:230, 100:240, 100:250, 100:260, 100:270, 100:280, 100:290, 100:300, 100:310, 100:320, 100:330, 100:340, 100:350, 100:360, 100:370, 100:380, 100:390, 100:400, 100:40 The ratios of the mobile phase to the volume of petroleum ether and ethyl acetate were 15:1, 10:1, 8:1, 6:1, 4:1, and 2:1, and the flow rate was 0.5L / h. The fractions 5-1 to 5-7 were obtained according to the TLC results. The fraction 5 was separated by a normal phase silica gel column, in which the mobile phase was petroleum ether / ethyl acetate, and the volume ratios of petroleum ether and ethyl acetate were 15:1, 10:1, 8:1, 6:1, 4:1, and 2:1, and the flow rate was 0.5L / h. The fractions 5-1 to 5-7 were obtained according to the TLC results. The fraction 5-3 was separated by a Sephadex column. The mixture was loaded onto an LH-20 gel column for separation, where the mobile phase was a mixture of dichloromethane and methanol in a volume ratio of 1:1. According to the TLC results, fraction 5-3-2 was obtained. Fraction 5-3-2 was loaded onto an Agilent C18 high performance liquid chromatography column for separation, where the mobile phase was a 35% aqueous methanol solution, the flow rate was 3 mL / min, and the detector was a 210 and 254 nm ultraviolet detector. Monomeric compound 1 was obtained, with a retention time of 28 minutes. Fraction 5-7 was loaded onto a Sephadex LH-20 gel column for separation, where the mobile phase was a mixture of dichloromethane and methanol in a volume ratio of 1:1. According to the TLC results, fraction 5-7-3 was obtained. Fraction 5-7-3 was loaded onto an Agilent C18 high performance liquid chromatography column for separation, where the mobile phase was 25% acetonitrile aqueous solution, the flow rate was 3 mL / min, and the detector was a 210 and 254 nm ultraviolet detector. Monomeric compound 2 and monomeric compound 3 were obtained, with retention times of 30 minutes and 28 minutes, respectively.Fraction 5-4 was loaded onto a Sephadex LH-20 gel column for separation, where the mobile phase was a mixture of dichloromethane and methanol in a volume ratio of 1:1. According to the TLC results, fraction 5-4-2 was obtained. Fraction 5-4-2 was loaded onto an Agilent C18 high performance liquid chromatography column for separation, where the mobile phase was a 35% aqueous acetonitrile solution, the flow rate was 3 mL / min, and the detector was a 210 and 254 nm ultraviolet detector. Monomeric compound 4 was obtained, with a retention time of 31 minutes.

[0021] The spectral data of the monomer compound 1 is as shown below. 1 H NMR (500 Hz, DMSO-d 6 ) δ : 9.26 (1H, s), 6.30 (1H, d, J = 1.85 Hz), 6.21 (1H, d, J = 1.85 Hz), 3.67 (2H, s), 3.64 (3H, s), 2.08 (3H, s) 1.86 (3H, s). 13 C HMR (125 Hz, DMSO-d 6 ) δ : 136.0 (C-1), 115.7 (C-2), 156.6 (C-3), 100.1 (C-4), 157.9 (C-5), 107.7 (C-6), 49.1 (C-7), 206.4 (C-8), 29.7 (C-9), 11.5 (C-10), 55.2 (C-11).

[0022] The HMBC spectrum of monomer compound 1 is shown below. [ka]

[0023] The spectral data of the monomer compound 2 is as shown below. 1 H NMR (500 Hz, DMSO-d 6) δ : 8.91 (1H, s),6.32 (1H, s), 4.57 (1H, d, J = 4.7 Hz) 3.73 (1H, m), 3.66 (3H, s), 2.73 (1H, dd, J = 13.4, 6.3 Hz), 2.60 (1H, dd, J = 13.4, 6.3 Hz), 2.03 (3H, s), 2.02 (3H, s), 1.01 (3H, d, J = 6.2 Hz). 13 C HMR (125 Hz, DMSO-d 6 ) δ : 138.5 (C-1), 115.0 (C-2), 155.7 (C-3), 97.1 (C-4), 153.8 (C-5), 114.8 (C-6), 39.7 (C-7), 67.2 (C-8), 23.7 (C-9), 12.2 (C-10), 55.5 (C-11), 12.4 (C-12).

[0024] The HMBC spectrum of monomer compound 2 is shown below. [ka]

[0025] The spectral data of monomeric compound 3 is shown below. 1 H NMR (500 Hz, DMSO-d 6 ) δ : 8.69 (1H, s), 6.62 (1H, d, J = 8.7 Hz), 6.66 (1H, d, J = 8.7 Hz), 4.45 (1H, s), 3.67 (3H, s), 2.59 (2H, m), 1.46 (2H, m), 0.91 (3H, t, J = 7.3 Hz). 13 C HMR (125 Hz, DMSO-d 6) δ : 130.1 (C-1),129.1 (C-2,), 151.0 (C-3), 109.8 (C-4), 114.4 (C-5), 149.6 (C-6), 28.6 (C-7), 23.6 (C-8), 14.9 (C-9), 54.6 (C-10), 56.5 (C-11).

[0026] The HMBC spectrum of monomer compound 3 is shown below. [ka]

[0027] The spectral data of the monomer compound 4 is as follows: 1 H NMR (500 Hz, DMSO-d 6 ) δ : 7.07 (1H, s),6.88 (1H, s), 4.50 (1H, d, J = 15.5 Hz),4.74 (1H, d, J = 15.5 Hz), 3.83 (3H, s),3.73 (1H, m), 2.86 (1H, d, J = 15.7 Hz),2.49 (1H, d, J = 15.7 Hz), 1.30 (3H, d, J = 6.1 Hz). 13 C HMR (125 Hz, DMSO-d 6 ) δ : 111.7 (C-1), 130.6 (C-2), 120.6 (C-3), 155.5 (C-4), 96.7 (C-5), 149.7 (C-6), 112.7 (C-7), 139.8 (C-8), 159.0 (C-9), 32.1 (C-10), 69.9 (C-11), 21.8 (C-12), 63.9 (C-13), 56.6 (C-14).

[0028] The HMBC spectrum of monomer compound 4 is shown below. [ka]

[0029] Example 2 Study on the anti-inflammatory activity of compounds 1 to 4 prepared in Example 1 Culture of mouse RAW 264.7 macrophages: RAW 264.7 macrophages were seeded in high-sugar DMEM medium containing 10% fetal bovine serum (<0.5 EU / ml), 1% penicillin and streptomycin, and incubated at 37°C in 5% CO. 2 Place in an incubator and culture. When cell coverage reaches approximately 90%, discard the supernatant and directly add 37°C medium and spray onto the plate to subculture. Take the cells in the logarithmic growth phase and use them in subsequent experiments.

[0030] Preparation of LPS-induced RAW 264.7 macrophage inflammation model: RAW 264.7 cells in logarithmic growth phase were taken and 1 × 10 cells were cultured per well. 4 The cells are seeded in a 96-well cell culture plate, and after 24 hours for the cells to adhere, the normal control group, LPS model group, positive control group, and compound group are placed, with 6 wells for each group. For the normal control group and LPS model group, cells are first cultured in serum-free DMEM medium, for the compound group, cells are cultured in serum-free DMEM containing compounds 1 to 4 at final concentrations of 80, 40, 20, and 10 μM, respectively, and for the positive control group, cells are cultured in serum-free DMEM containing L-NAME (a nitric oxide synthase inhibitor) at a final concentration of 200 μM. After culturing the cells for 4 hours as described above, the normal control group was further cultured in serum-free DMEM, and the other groups were stimulated by adding LPS with a final concentration of 1 μg / mL. After 24 hours, 50 μL of medium was collected from each well, and the secretion of NO was detected by a nitric oxide screening kit. 10 μL of MTT with a concentration of 5 g / L was added to each well. After further culturing for 4 hours, the supernatant was discarded, and 150 μL of DMSO was added to each well, shaken for 10 minutes, and the absorbance of each well was measured at 570 nm.

[0031] The MTT results showed that the IC 50 is greater than 100 μM (IC 50The results of the anti-inflammatory experiment are shown in FIG. 1. The four compounds of the present invention inhibit the release of NO to different degrees at different concentrations, among which, compound 3 exhibits superior inhibitory activity to the positive control group at a concentration of 10 μM. It is clear that the four compounds have different degrees of anti-inflammatory activity.

[0032] Finally, the following should be mentioned: the above embodiments are only for explaining the technical means of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the above embodiments, it is possible to modify the technical means described in the above embodiments, or to implement equivalent replacements for part or all of the technical features, and it is understood by those skilled in the art that such modifications and replacements do not depart from the essence of the corresponding technical means of the embodiments of the present invention.

[0033] [Note] [Appendix 1] A polyketide compound having the structure shown in the following formula, or a pharma- ceutically acceptable salt thereof. [ka]

[0034] [Appendix 2] The endophytic fungus (Penicillium sp.) HJT-A-10 was deposited at the Center of Ordinary Microorganisms, China Committee for the Preservation and Management of Microbial Species, on May 6, 2022, with the deposit number CGMCC No. 40167, and the address of the depository institution is No. 3, Hall No. 1, Beichen West Road, Chaoyang District, Beijing.

[0035] [Appendix 3] Step (1) of inoculating the Penicillium sp. HJT-A-10 described in Appendix 2 into a solid medium and culturing it to obtain a solid fermentation product; The extract of the solid fermentation product obtained in step (1) is loaded onto a normal phase silica gel column, and gradient elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 100:0 to 100:100. Fractions 1 to 5 are obtained in sequence according to the TLC results. Then, fraction 5 is loaded onto a normal phase silica gel column, and gradient elution is performed using a mobile phase of petroleum ether / ethyl acetate with a volume ratio of 15:1 to 2:1. Fractions 5-1 to 5-7 are obtained in sequence according to the TLC results. Fraction 5-3 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 1:1. Fraction 5-3-2 is obtained in sequence according to the TLC results. Fraction 5-3-2 is loaded onto an Agilent C18 high performance liquid chromatography column, and elution is performed using a mobile phase of 35% aqueous methanol to obtain compound 1. Fraction 5-7 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a mobile phase of 35% aqueous methanol to obtain compound 2. and (2) loading the fraction 5-4 onto a Sephadex LH-20 gel column, eluting with a 1:1 volumetric ratio mixture of dichloromethane and methanol as the mobile phase, obtaining a fraction 5-7-3 based on the TLC results, loading the fraction 5-7-3 onto an Agilent C18 high performance liquid chromatography column, eluting with a 25% aqueous acetonitrile solution as the mobile phase, obtaining compound 2 and compound 3, loading the fraction 5-4 onto a Sephadex LH-20 gel column, eluting with a 1:1 volumetric ratio mixture of dichloromethane and methanol as the mobile phase, obtaining a fraction 5-4-2 based on the TLC results, loading the fraction 5-4-2 onto an Agilent C18 high performance liquid chromatography column, eluting with a 35% aqueous acetonitrile solution as the mobile phase, obtaining compound 4.

[0036] [Appendix 4] The method for producing the solid medium in step (1) is obtained by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / mL.

[0037] [Appendix 5] The method of claim 3, wherein in the loading step (2), 100-200 mesh silica gel is added to the solid fermentation product extract, stirred, and the solvent is evaporated to dryness, followed by packing into a column.

[0038] [Appendix 6] The method of claim 3, wherein in the gradient elution in step (2), the volume ratio of dichloromethane / methanol is 100:0, 100:1, 100:2, 100:3, 100:4, 100:5, 100:7, 100:10, 100:20, 100:50, or 100:100.

[0039] [Appendix 7] The method of claim 3, wherein in the gradient elution in step (2), the volume ratio of petroleum ether / ethyl acetate is 15:1, 10:1, 8:1, 6:1, 4:1, or 2:1.

[0040] [Appendix 8] A pharmaceutical composition comprising the polyketide compound described in Appendix 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0041] [Appendix 9] Use of the polyketide compound or a pharma- ceutically acceptable salt thereof according to Appendix 1 or the pharmaceutical composition according to Appendix 8 for the manufacture of an anti-inflammatory drug.

Claims

1. A polyketide compound having the structure shown in the following formula, or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】

2. Penicillium sp. HJT-A-10, deposited at the Center of Ordinary Microorganisms of the China Committee for the Preservation and Management of Microorganisms on May 6, 2022, with the deposit number CGMCC No. 40167, and the address of the depository institution is No. 3, Hall No. 1, Beichen West Road, Chaoyang District, Beijing.

3. (1) inoculating the Penicillium sp. HJT-A-10 according to claim 2 into a solid medium and culturing it to obtain a solid fermentation product; The solid fermentation product extract obtained in step (1) is loaded onto a normal-phase silica gel column, and gradient elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 100:0 to 100:

100. Fractions 1 to 5 are obtained in sequence according to the TLC results. Then, fraction 5 is loaded onto a normal-phase silica gel column, and gradient elution is performed using a mobile phase of petroleum ether / ethyl acetate with a volume ratio of 15:1 to 2:

1. Fractions 5-1 to 5-7 are obtained in sequence according to the TLC results. Fraction 5-3 is loaded onto a Sephadex LH-20 gel column, and elution is performed using a mobile phase of dichloromethane / methanol with a volume ratio of 1:

1. Fraction 5-3-2 is obtained in sequence according to the TLC results. Fraction 5-3-2 is loaded onto an Agilent C18 high performance liquid chromatography column, and elution is performed using a mobile phase of 35% aqueous methanol solution to obtain compound 1. Fraction 5-7 is eluted onto Sephadex LH-20 gel column. and loading the fraction 5-4 onto a Sephadex LH-20 gel column, eluting with a 1:1 volumetric ratio dichloromethane / methanol mixture as the mobile phase, obtaining fraction 5-7-3 based on the TLC results, loading fraction 5-7-3 onto an Agilent C18 high performance liquid chromatography column, eluting with a 25% aqueous acetonitrile solution as the mobile phase, obtaining compound 2 and compound 3, loading fraction 5-4 onto a Sephadex LH-20 gel column, eluting with a 1:1 volumetric ratio dichloromethane / methanol mixture as the mobile phase, obtaining fraction 5-4-2 based on the TLC results, loading fraction 5-4-2 onto an Agilent C18 high performance liquid chromatography column, eluting with a 35% aqueous acetonitrile solution as the mobile phase, obtaining compound 4. The method for producing a polyketide compound according to claim 1, comprising the steps of: (2)

4. The method according to claim 3, wherein the solid medium in step (1) is prepared by preparing rice and pure water in a mass / volume ratio of 80:80 to 120 g / mL.

5. The method according to claim 3, wherein in the loading step (2), 100-200 mesh silica gel is added to the solid fermentation product extract, stirred, and the solvent is evaporated to dryness, followed by packing into a column.

6. 4. The method of claim 3, wherein in the gradient elution in step (2), the volume ratio of dichloromethane / methanol is 100:0, 100:1, 100:2, 100:3, 100:4, 100:5, 100:7, 100:10, 100:20, 100:50, or 100:

100.

7. 4. The method of claim 3, wherein in the gradient elution in step (2), the volume ratio of petroleum ether / ethyl acetate is 15:1, 10:1, 8:1, 6:1, 4:1, or 2:

1.

8. A pharmaceutical composition comprising the polyketide compound of claim 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

9. Use of the polyketide compound or a pharma- ceutically acceptable salt thereof according to claim 1 or the pharmaceutical composition according to claim 8 for the manufacture of an anti-inflammatory drug.

Citation Information

Patent Citations

  • Deep-sea fungi derived polyketides, as well as preparation method and application thereof

    CN110724642A

  • Preparation method and application of polyketone compound with anti-novel coronavirus activity

    CN113248369A

  • Polyketone compound and preparation method thereof

    CN113277998A

  • Anti-inflammatory and psoriasis therapy and protein kinase inhibition with hydroxylstilbenes and novel stilbene derivatives and analogues

    JP2003516400A

  • Anti-inflammatory or antidiabetic composition comprising metabolite of marine-drived fungus penicillium glabrum SF-7123

    WO2021225363A1

Cited By

  • Polyketide compounds having anti-inflammatory activity and methods for producing and using same

    JP2024542324A

  • Polyketide compounds having anti-inflammatory activity and uses thereof

    JP7777369B2